The role drives the commercial development and successful global launch of ALXN-2230 for rare neurology indications including IIM, wAIHA, and gMG.
Base: $231,988.80 - $347,983.20 USD annually; Bonus/Equity: Short-term incentive bonus and equity-based long-term incentive program available; Benefits: 401(k), paid vacation, health/dental/vision coverage
Must-have
Nice-to-have
Not specified